These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 32054272)

  • 1. Effectiveness and safety of adalimumab biosimilar ABP 501 in Crohn's disease: an observational study.
    Ribaldone DG; Caviglia GP; Pellicano R; Vernero M; Saracco GM; Morino M; Astegiano M
    Rev Esp Enferm Dig; 2020 Mar; 112(3):195-200. PubMed ID: 32054272
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effectiveness and safety of switching to adalimumab biosimilar ABP 501 in Crohn's disease.
    Viscido A; Latella G
    Rev Esp Enferm Dig; 2021 Feb; 113(2):154-155. PubMed ID: 33207902
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Switching From Originator Adalimumab to the Biosimilar SB5 in Patients With Inflammatory Bowel Disease: Short-term Experience From a Single Tertiary Clinical Centre.
    Lukas M; Malickova K; Kolar M; Bortlik M; Vasatko M; Machkova N; Hruba V; Duricova D; Lukas M
    J Crohns Colitis; 2020 Jul; 14(7):915-919. PubMed ID: 31905382
    [TBL] [Abstract][Full Text] [Related]  

  • 4. SPOSAB ABP 501: A Sicilian Prospective Observational Study of Patients with Inflammatory Bowel Disease Treated with Adalimumab Biosimilar ABP 501.
    Macaluso FS; Cappello M; Busacca A; Fries W; Viola A; Costantino G; Magnano A; Vinci E; Ferracane C; Privitera AC; Piccillo G; Belluardo N; Giangreco E; Romano C; Citrano M; Graziano F; Garufi S; Bertolami C; Ventimiglia M; Scrivo B; Teresi G; Renna S; Rizzuto G; Casà A; Orlando A;
    J Gastroenterol Hepatol; 2021 Nov; 36(11):3041-3049. PubMed ID: 34152636
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of Performances of Adalimumab Biosimilars SB5, ABP501, GP2017, and MSB11022 in Treating Patients with Inflammatory Bowel Diseases: A Real-Life, Multicenter, Observational Study.
    Tursi A; Mocci G; Allegretta L; Aragona G; Bianco MA; Colucci R; Cuomo A; Della Valle N; Ferronato A; Forti G; Gaiani F; Giorgetti G; Graziani MG; Lofano K; Lorenzetti R; Larussa T; Penna A; Pica R; Pranzo G; Rodino' S; Scarcelli A; Zampaletta C; Bassotti G; Cazzato AI; Chiri S; Clemente V; Cocco A; De' Angelis G; Donnarumma L; Faggiani R; Graziosi C; Le Grazie M; Luzza F; Meucci C; Monterubbianesi R; Pagnini C; Perazzo P; Picchio M; Sacco R; Sebkova L; Serio M; Napolitano D; Pugliese D; Scaldaferri F; Schiavoni E; Turchini L; Armuzzi A; Elisei W; Maconi G; Papa A
    Inflamm Bowel Dis; 2023 Mar; 29(3):376-383. PubMed ID: 35579320
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy, tolerability, and safety of infliximab biosimilar in comparison to originator biologic and adalimumab in patients with Crohn disease.
    Kaniewska M; Rosołowski M; Rydzewska G
    Pol Arch Intern Med; 2019 Aug; 129(7-8):484-489. PubMed ID: 31316042
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Real-world outcomes of switching from adalimumab originator to adalimumab biosimilar in patients with inflammatory bowel disease: The ADA-SWITCH study.
    Casanova MJ; Nantes Ó; Varela P; Vela-González M; Rivero M; Sierra-Gabarda O; Riestra S; Barreiro-de Acosta M; Martín-Rodríguez MDM; Gargallo-Puyuelo CJ; Reygosa C; Muñoz R; de la Filia-Molina IG; Núñez-Ortiz A; Kolle L; Calafat M; Huguet JM; Iglesias-Flores E; Martínez-Pérez TJ; Bosch O; Duque-Alcorta JM; Frago-Larramona S; Van Domselaar M; González-Cosano VM; Bujanda L; Rubio S; Mancebo A; Castro B; García-López S; de Francisco R; Nieto-García L; Laredo V; Gutiérrez-Casbas A; Mesonero F; Leo-Carnerero E; Cañete F; Ruiz L; Gros B; Del Moral-Martínez M; Rodríguez C; Chaparro M; Gisbert JP
    Aliment Pharmacol Ther; 2023 Jul; 58(1):60-70. PubMed ID: 37089065
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and efficacy of BI 695501 versus adalimumab reference product in patients with advanced Crohn's disease (VOLTAIRE-CD): a multicentre, randomised, double-blind, phase 3 trial.
    Hanauer S; Liedert B; Balser S; Brockstedt E; Moschetti V; Schreiber S
    Lancet Gastroenterol Hepatol; 2021 Oct; 6(10):816-825. PubMed ID: 34388360
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A switch from originator-adalimumab to the biosimilar SB5 in patients with Crohn's disease: an analysis of two propensity score-matched cohorts.
    Lukas M; Kolar M; Reissigova J; Duricova D; Machkova N; Hruba V; Lukas M; Vasatko M; Jirsa J; Pudilova K; Malickova K
    Scand J Gastroenterol; 2022 Jul; 57(7):814-824. PubMed ID: 35234552
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effectiveness and safety of adalimumab biosimilar in patients with inflammatory bowel disease.
    Poquet-Jornet JE; Ibáñez-Sala I; Garrigues-Pelufo T; Munilla-Das A; Valdivia-Pérez A; Carrera-Hueso FJ
    Farm Hosp; 2024 Apr; ():. PubMed ID: 38570210
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Switching maintenance infliximab therapy to biosimilar infliximab in inflammatory bowel disease patients.
    Eberl A; Huoponen S; Pahikkala T; Blom M; Arkkila P; Sipponen T
    Scand J Gastroenterol; 2017 Dec; 52(12):1348-1353. PubMed ID: 28838273
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A single-centre, observational, retrospective, real-life study evaluating adalimumab biosimilar ABP 501 in the treatment of plaque-type psoriasis and psoriatic arthritis in originator-naïve patients and in patients undergoing non-medical switch from originator.
    Giunta A; Zangrilli A; Bavetta M; Manfreda V; Pensa C; Bianchi L
    Curr Med Res Opin; 2021 Jul; 37(7):1099-1102. PubMed ID: 34011212
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Real-World Experience of Adalimumab Biosimilar (ABP 501) Use in Patients with Inflammatory Bowel Disease in Europe.
    Jin R; Nduka C; Courmier D; Knight H; Meadows R; Piercy J; Cummings JRF; Radziszewski W
    Adv Ther; 2024 Jan; 41(1):331-348. PubMed ID: 37957522
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum concentrations after switching from originator infliximab to the biosimilar CT-P13 in patients with quiescent inflammatory bowel disease (SECURE): an open-label, multicentre, phase 4 non-inferiority trial.
    Strik AS; van de Vrie W; Bloemsaat-Minekus JPJ; Nurmohamed M; Bossuyt PJJ; Bodelier A; Rispens T; van Megen YJB; D'Haens GR;
    Lancet Gastroenterol Hepatol; 2018 Jun; 3(6):404-412. PubMed ID: 29606564
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effectiveness and safety of switching to adalimumab biosimilar ABP 501 in Crohn's disease: the extrapolation concept.
    Ribaldone DG; Vernero M; Astegiano M
    Rev Esp Enferm Dig; 2021 Feb; 113(2):155. PubMed ID: 33207912
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tumor necrosis factor-alpha antibody for maintenance of remission in Crohn's disease.
    Behm BW; Bickston SJ
    Cochrane Database Syst Rev; 2008 Jan; (1):CD006893. PubMed ID: 18254120
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mucosal Healing and Clinical Efficacy of Adalimumab in Small Intestinal Crohn's Disease (SIMCHA Study): Final Results From a Prospective, Open-Label, Single-Arm Study.
    Wetwittayakhlang P; Verdon C; Starr M; Hahn GD; Golovics PA; Bessissow T; Afif W; Wild G; Bitton A; Lakatos PL
    Turk J Gastroenterol; 2023 Jun; 34(6):603-610. PubMed ID: 37162506
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effectiveness and Safety of Adalimumab Biosimilar SB5 in Inflammatory Bowel Disease: Outcomes in Originator to SB5 Switch, Double Biosimilar Switch and Bio-Naïve SB5 Observational Cohorts.
    Derikx LAAP; Dolby HW; Plevris N; Lucaciu L; Rees CS; Lyons M; Siakavellas SI; Constantine-Cooke N; Jenkinson P; Su S; O'Hare C; Kirckpatrick L; Merchant LM; Noble C; Arnott ID; Jones GR; Lees CW
    J Crohns Colitis; 2021 Dec; 15(12):2011-2021. PubMed ID: 34089587
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of tight control management on Crohn's disease (CALM): a multicentre, randomised, controlled phase 3 trial.
    Colombel JF; Panaccione R; Bossuyt P; Lukas M; Baert F; Vaňásek T; Danalioglu A; Novacek G; Armuzzi A; Hébuterne X; Travis S; Danese S; Reinisch W; Sandborn WJ; Rutgeerts P; Hommes D; Schreiber S; Neimark E; Huang B; Zhou Q; Mendez P; Petersson J; Wallace K; Robinson AM; Thakkar RB; D'Haens G
    Lancet; 2017 Dec; 390(10114):2779-2789. PubMed ID: 29096949
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ABP 501 (adalimumab-atto) in the treatment of inflammatory bowel disease: an example of evidence-based extrapolation.
    Muñoz Núñez F; Taxonera C; Marrón J
    Rev Esp Enferm Dig; 2021 Oct; 113(10):737-738. PubMed ID: 33648343
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.